Patents by Inventor Maximilian BIELOHUBY

Maximilian BIELOHUBY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
    Patent number: 11352405
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 7, 2022
    Assignee: SANOFI
    Inventors: Aimo Kannt, Maximilian Bielohuby, Ralf Elvert, Michael Wagner, Martin Bossart, Torsten Haack, Stephanie Keil, Werner Seiz
  • NOVEL CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN
    Publication number: 20210170033
    Abstract: The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 10, 2021
    Inventors: Stefan PETRY, Elisabeth DEFOSSA, Michael PODESCHWA, Volker DERDAU, Hans MATTER, Nis HALLAND, Kaihui HU HE, Matthias DREYER, Maximilian BIELOHUBY, Melissa BESENIUS, Meltsje DE HOOP
  • GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
    Publication number: 20200216510
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 9, 2020
    Inventors: Aimo KANNT, Maximilian BIELOHUBY, Ralf ELVERT, Michael WAGNER, Martin BOSSART, Torsten HAACK, Stephanie KEIL, Werner SEIZ